Cite
HARVARD Citation
Bardia, A. et al. (2023). P018 TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator's choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy. Breast. pp. S23-. [Online].